BILLIONTOONE INC CL A (BLLN) Stock Price, Forecast & Analysis
NASDAQ:BLLN • US0901681058
BLLN Key Statistics, Chart & Performance
The current stock price of BLLN is 88.61 USD. In the past month the price decreased by -6.45%.
BLLN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BLLN.
BLLN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLLN. The financial health of BLLN is average, but there are quite some concerns on its profitability.
BLLN Financial Highlights
Over the last trailing twelve months BLLN reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 49.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.69% | ||
| ROE | -23.11% | ||
| Debt/Equity | 0.31 |
BLLN Forecast & Estimates
14 analysts have analysed BLLN and the average price target is 137.99 USD. This implies a price increase of 55.73% is expected in the next year compared to the current price of 88.61.
For the next year, analysts expect an EPS growth of 117.54% and a revenue growth 98.01% for BLLN
BLLN Ownership
BLLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.84 | 99.625B | ||
| CI | THE CIGNA GROUP | 9.32 | 76.783B | ||
| LH | LABCORP HOLDINGS INC | 15.66 | 23.43B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.68 | 23.012B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.25 | 22.794B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.509B | ||
| DVA | DAVITA INC | 11.26 | 10.21B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 28.36 | 7.008B | ||
| CHE | CHEMED CORP | 18.44 | 6.701B | ||
| OPCH | OPTION CARE HEALTH INC | 18.58 | 5.622B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BLLN
Company Profile
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
Company Info
BILLIONTOONE INC CL A
1035 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 0
Phone: 16504602552
BILLIONTOONE INC CL A / BLLN FAQ
What does BILLIONTOONE INC CL A do?
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
What is the current price of BLLN stock?
The current stock price of BLLN is 88.61 USD. The price decreased by -1.2% in the last trading session.
Does BILLIONTOONE INC CL A pay dividends?
BLLN does not pay a dividend.
What is the ChartMill rating of BILLIONTOONE INC CL A stock?
BLLN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of BILLIONTOONE INC CL A (BLLN)?
You can find the ownership structure of BILLIONTOONE INC CL A (BLLN) on the Ownership tab.
What is the Short Interest ratio of BILLIONTOONE INC CL A (BLLN) stock?
The outstanding short interest for BILLIONTOONE INC CL A (BLLN) is 2.8% of its float.